Stockreport

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

TRACON Pharmaceuticals, Inc.  (TCON) 
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) [Read more]